Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Deucravacitinib for Patients with Active Psoriatic Arthritis New to Biologic Treatments

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called deucravacitinib in individuals with Psoriatic Arthritis. Psoriatic Arthritis is a condition that causes joint pain and swelling, often accompanied by skin symptoms like psoriasis. The medication being tested, deucravacitinib, is taken as a film-coated tablet and is being compared to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to evaluate how effective and safe deucravacitinib is for people with active Psoriatic Arthritis who have not previously been treated with biologic disease-modifying anti-rheumatic drugs. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will take the medication or placebo for a period of time, and their health will be monitored to assess any changes in their condition. The main goal is to see if there is an improvement in joint symptoms and overall health after 16 weeks of treatment. The study will also look at other health measures to understand the full impact of the treatment. This research aims to provide valuable information about the potential benefits of deucravacitinib for people living with Psoriatic Arthritis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit. During this visit, your eligibility will be confirmed based on specific criteria, such as having psoriatic arthritis for at least 3 months and meeting certain medical conditions.

    You will undergo various assessments, including joint examinations and blood tests, to ensure you meet the study requirements.

  2. Step 2

    Randomization

    After confirming eligibility, you will be randomly assigned to one of two groups. One group will receive the active medication, deucravacitinib, and the other will receive a placebo, which looks like the medication but has no active ingredients.

    This process is double-blind, meaning neither you nor the study team will know which group you are in.

  3. Step 3

    Medication administration

    If you are in the active medication group, you will take a deucravacitinib 6 mg tablet once daily by mouth. If you are in the placebo group, you will take a placebo tablet once daily by mouth.

    The duration of this phase is 16 weeks, during which you will continue taking the assigned tablet daily.

  4. Step 4

    Follow-up visits

    Throughout the 16-week period, you will have regular follow-up visits. These visits are essential for monitoring your health and the effects of the treatment.

    During these visits, you will undergo various assessments, including joint examinations, blood tests, and questionnaires about your health and symptoms.

  5. Step 5

    End of treatment evaluation

    At the end of the 16-week treatment period, you will have a final evaluation. This will include a comprehensive assessment of your condition and any changes in your symptoms.

    The study team will review the results to determine the effectiveness and safety of the treatment.

Who can join the trial?

7 criteria

  • Must have been diagnosed with psoriatic arthritis (PsA) for at least 3 months before joining the study.
  • Must meet the Classification Criteria for Psoriatic Arthritis (CASPAR) at the time of joining the study. This is a set of guidelines used to confirm the diagnosis of psoriatic arthritis.
  • Must have active plaque psoriatic skin lesions or a documented medical history of plaque psoriasis (PsO) at the time of joining the study. Plaque psoriasis is a skin condition that causes red, scaly patches.
  • Must have active arthritis with at least 3 swollen joints and 3 tender joints at the time of joining the study and on the first day of the study.
  • Must have a high sensitivity C-reactive protein (hsCRP) level of 3 mg/L or higher at the time of joining the study. hsCRP is a blood test marker for inflammation in the body.
  • Must have at least one PsA-related joint erosion in the hand or foot, confirmed by an X-ray during the screening period.
  • Both male and female participants are eligible.

Who cannot join the trial?

10 criteria

  • Having any other **active autoimmune disease**. This means your immune system is attacking your own body, causing other health problems.
  • Having a **serious infection**. This is an illness caused by bacteria, viruses, or other germs that can make you very sick.
  • Having a history of **cancer** within the last 5 years, except for some types of skin cancer. Cancer is a disease where cells in the body grow uncontrollably.
  • Being pregnant or breastfeeding. This means you are expecting a baby or feeding a baby with your milk.
  • Having **liver disease**. This is a condition where your liver is not working properly.
  • Having **kidney disease**. This is a condition where your kidneys are not working properly.
  • Having a history of **heart attack** or **stroke**. A heart attack is when blood flow to the heart is blocked, and a stroke is when blood flow to the brain is blocked.
  • Using certain medications that might interfere with the study. This means taking drugs that could affect the results of the trial.
  • Having a history of **drug or alcohol abuse**. This means using drugs or alcohol in a way that is harmful to your health.
  • Being unable to follow the study procedures. This means not being able to do what the study requires.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Deucravacitinib is a medication being studied for its potential to help people with active psoriatic arthritis, a condition that causes joint pain and swelling. This medication works by targeting specific pathways in the immune system that are involved in inflammation. By doing so, it aims to reduce the symptoms of psoriatic arthritis, such as pain and swelling, and improve the overall quality of life for those affected by this condition. The study is focused on people who have not previously been treated with biologic drugs, which are a type of advanced therapy for autoimmune diseases.

What is already known about the treatment

Deucravacitinib – Deucravacitinib is administered orally in the form of a tablet. It is currently being studied in clinical trials for its effectiveness and safety in treating active psoriatic arthritis, particularly in patients who have not previously used biologic disease-modifying anti-rheumatic drugs. The main therapeutic indication for deucravacitinib is active psoriatic arthritis, a condition that causes joint pain and swelling. At the molecular level, deucravacitinib works by selectively inhibiting an enzyme called TYK2, which plays a role in the inflammatory process. It is classified pharmacologically as a selective TYK2 inhibitor.

Investigated diseases

Psoriatic Arthritis – Psoriatic Arthritis is a chronic inflammatory disease that affects the joints and areas where tendons and ligaments connect to bone. It often occurs in people who have psoriasis, a condition characterized by red patches of skin topped with silvery scales. The disease can cause joint pain, stiffness, and swelling, which may worsen over time. It typically affects the fingers and toes, but can also involve the spine and other joints. As the disease progresses, it can lead to joint damage and reduced range of motion. Enthesitis, dactylitis, and changes in nail appearance are also common features of this condition.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506256-25-00Protocol codeIM011-054Estimated enrolment650 patientsSponsorBristol-Myers Squibb Services Unlimited Company

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.